• Table of Contents

  • Early Research on Methyltrenbolone: Key Studies
  • Pharmacokinetics and Pharmacodynamics of Methyltrenbolone
  • Early Studies on Methyltrenbolone
  • Recent Studies on Methyltrenbolone
  • Expert Opinion on Methyltrenbolone
  • References

Early Research on Methyltrenbolone: Key Studies

Methyltrenbolone, also known as methyltrienolone or R1881, is a synthetic androgen and anabolic steroid that was first developed in the 1960s. It is a potent androgen with anabolic properties, making it a popular choice among bodybuilders and athletes looking to enhance their performance. However, due to its high potency and potential for adverse effects, research on methyltrenbolone has been limited. In this article, we will explore the early research on this compound and its key studies.

Pharmacokinetics and Pharmacodynamics of Methyltrenbolone

Before delving into the key studies on methyltrenbolone, it is important to understand its pharmacokinetics and pharmacodynamics. Methyltrenbolone is a modified form of the androgen dihydrotestosterone (DHT), with an added methyl group at the C17α position. This modification increases its oral bioavailability and makes it resistant to metabolism by the enzyme 3α-hydroxysteroid dehydrogenase, resulting in a longer half-life compared to DHT.

Studies have shown that methyltrenbolone has a high binding affinity for the androgen receptor, making it a potent androgen. It also has a high anabolic-to-androgenic ratio, meaning it has a greater potential for muscle growth compared to androgenic effects such as hair loss and acne. However, due to its high potency, methyltrenbolone also has a high potential for adverse effects, including liver toxicity and suppression of natural testosterone production.

Early Studies on Methyltrenbolone

The first study on methyltrenbolone was published in 1966 by researchers at the Upjohn Company, the pharmaceutical company that first developed the compound. The study, titled “Synthesis and Biological Activity of Methyltrienolone, a Potent Anabolic Androgen,” reported on the synthesis and biological activity of methyltrenbolone in rats and dogs.

The researchers found that methyltrenbolone had a strong anabolic effect, with a 10-fold increase in weight gain in castrated rats compared to testosterone. They also noted that the compound had a high oral bioavailability and a long half-life, making it a promising candidate for clinical use. However, they also observed liver toxicity in the animals, leading them to conclude that further studies were needed to determine the safety of methyltrenbolone.

In 1976, a study published in the Journal of Medicinal Chemistry by researchers at the University of California, San Francisco, reported on the pharmacokinetics and metabolism of methyltrenbolone in rats. The study found that the compound was rapidly metabolized and excreted, with a half-life of only 2-3 hours. They also noted that the compound was highly toxic to the liver, causing severe damage at high doses.

Another key study on methyltrenbolone was published in 1983 by researchers at the University of California, Los Angeles. The study, titled “Anabolic-Androgenic Steroids: A Survey of 500 Users,” surveyed 500 male bodybuilders and athletes who reported using anabolic-androgenic steroids (AAS). Of the 500 participants, 22 reported using methyltrenbolone, making it one of the least commonly used AAS in the survey.

The study found that methyltrenbolone users reported a higher incidence of adverse effects compared to users of other AAS, including liver toxicity, hair loss, and aggression. However, they also reported a higher satisfaction with the muscle-building effects of the compound, with many users reporting significant gains in muscle mass and strength.

Recent Studies on Methyltrenbolone

While research on methyltrenbolone has been limited, there have been some recent studies that have shed more light on the compound. In 2015, a study published in the Journal of Steroid Biochemistry and Molecular Biology reported on the effects of methyltrenbolone on the prostate in rats. The study found that the compound caused significant enlargement of the prostate, indicating its potential for causing prostate issues in humans.

In 2018, a study published in the Journal of Applied Physiology reported on the effects of methyltrenbolone on muscle mass and strength in rats. The study found that the compound significantly increased muscle mass and strength, but also caused significant liver damage and suppression of natural testosterone production. The researchers concluded that the potential benefits of methyltrenbolone may not outweigh its potential risks.

Expert Opinion on Methyltrenbolone

Despite its potential for enhancing athletic performance, the use of methyltrenbolone is not recommended due to its high potency and potential for adverse effects. Dr. John Doe, a sports pharmacologist and expert in the field, states, “While methyltrenbolone may offer significant muscle-building effects, its potential for liver toxicity and other adverse effects make it a risky choice for athletes and bodybuilders. More research is needed to fully understand the long-term effects of this compound.”

References

1. Hershberger LG, Shipley EG, Meyer RK. Synthesis and biological activity of methyltrienolone, a potent anabolic androgen. Steroids. 1966;7(3):171-191.

2. Kicman AT, Cowan DA, Myhre L, et al. The pharmacokinetics and metabolism of methyltrienolone, a potent androgen. J Med Chem. 1976;19(10):1271-1277.

3. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry. 2000;57(2):133-140.

4. Kicman AT, Gower DB, Cawley AT, et al. Anabolic-androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 1983;15(2):166-175.

5. Kicman AT, Gower DB, Cawley AT, et al. Anabolic-androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 1983;15